Suppr超能文献

骨保护素、核因子-κB 配体可溶性受体激活剂与 1 型糖尿病患儿及青少年亚临床动脉粥样硬化的关系

Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor- κ B Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus.

机构信息

2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece.

出版信息

Int J Endocrinol. 2013;2013:102120. doi: 10.1155/2013/102120. Epub 2013 Oct 30.

Abstract

Aims. To evaluate carotid intima-media thickness (cIMT) and biomarkers of the osteoprotegerin/receptor activator of nuclear factor- κ B ligand (OPG/RANKL) system in type 1 diabetes (T1DM) children and adolescents and controls. Subjects and Methods. Fifty six T1DM patients (mean ± SD age: 12.0 ± 2.7 years, diabetes duration: 5.42 ± 2.87 years and HbA1c: 8.0 ± 1.5%) and 28 healthy matched controls, were studied with anthropometric and laboratory measurements, including serum OPG, soluble RANKL (sRANKL) and cIMT. Results. Anthropometric, laboratory, and cIMT measurements were similar between T1DM youngsters and controls. However patients with longer diabetes duration (>/7.0 years) had indicatively higher cIMT (cIMT = 0.49 vs 0.44 mm, P 0.072) and triglyceride levels than the rest of the patients (93.7 vs 64.6 mg/dl, P 0.025). Both in the total study population (β 0.418, P 0.027) and among T1DM patients separately (β 0.604, P 0.013), BMI was the only factor associated with cIMT. BMI was further associated with OPG in both groups (β -0.335, P 0.003 and β -0.356, P 0.008 respectively), while sRANKL levels were not associated with any factor. Conclusions. BMI was the strongest independent predictor of cIMT among the whole population, and especially in diabetics, suggesting a possible synergistic effect of diabetes and adiposity on atherosclerotic burden. BMI was overall strongly associated with circulating OPG, but the causes of this association remain unclear.

摘要

目的。评估 1 型糖尿病(T1DM)儿童和青少年及对照者的颈动脉内膜中层厚度(cIMT)和护骨素/核因子-κ B 配体受体激活剂(OPG/RANKL)系统的生物标志物。

对象和方法。研究了 56 名 T1DM 患者(平均年龄±标准差为 12.0±2.7 岁,糖尿病病程:5.42±2.87 年,HbA1c:8.0±1.5%)和 28 名健康匹配的对照者,进行了人体测量学和实验室测量,包括血清 OPG、可溶性 RANKL(sRANKL)和 cIMT。

结果。T1DM 青少年和对照组的人体测量学、实验室和 cIMT 测量结果相似。然而,糖尿病病程较长(>/7.0 年)的患者 cIMT 较高(cIMT=0.49 vs 0.44mm,P=0.072),甘油三酯水平也高于其余患者(93.7 vs 64.6mg/dl,P=0.025)。在整个研究人群中(β=0.418,P=0.027)和在 T1DM 患者中分别(β=0.604,P=0.013),BMI 是与 cIMT 唯一相关的因素。BMI 与两组的 OPG 均相关(β=-0.335,P=0.003 和 β=-0.356,P=0.008),而 sRANKL 水平与任何因素均无关。

结论。BMI 是整个人群中 cIMT 的最强独立预测因子,尤其是在糖尿病患者中,提示糖尿病和肥胖对动脉粥样硬化负担可能存在协同作用。BMI 与循环 OPG 总体上密切相关,但这种关联的原因尚不清楚。

相似文献

7
Circulating calcification inhibitors are associated with arterial damage in pediatric patients with primary hypertension.
Pediatr Nephrol. 2021 Aug;36(8):2371-2382. doi: 10.1007/s00467-021-04957-5. Epub 2021 Feb 18.
8
Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker.
BMC Pediatr. 2017 Mar 9;17(1):69. doi: 10.1186/s12887-017-0820-1.
9
Osteoprotegerin levels in children with subclinical hypothyroidism.
Acta Paediatr. 2020 Dec;109(12):2770-2774. doi: 10.1111/apa.15291. Epub 2020 Apr 24.

引用本文的文献

2
Mechanisms of altered bone remodeling in children with type 1 diabetes.
World J Diabetes. 2021 Jul 15;12(7):997-1009. doi: 10.4239/wjd.v12.i7.997.
3
Circulating calcification inhibitors are associated with arterial damage in pediatric patients with primary hypertension.
Pediatr Nephrol. 2021 Aug;36(8):2371-2382. doi: 10.1007/s00467-021-04957-5. Epub 2021 Feb 18.
5
Phenolic constituents and modulatory effects of Raffia palm leaf () extract on carbohydrate hydrolyzing enzymes linked to type-2 diabetes.
J Tradit Complement Med. 2017 Feb 4;7(4):494-500. doi: 10.1016/j.jtcme.2017.01.003. eCollection 2017 Oct.

本文引用的文献

1
Cardiovascular risk in the young type 1 diabetes population with a low 10-year, but high lifetime risk of cardiovascular disease.
Diabetes Obes Metab. 2013 Mar;15(3):198-203. doi: 10.1111/dom.12013. Epub 2012 Oct 24.
2
Repeatability and reproducibility of ultrasonographic measurement of carotid intima thickness.
J Clin Ultrasound. 2012 Feb;40(2):79-84. doi: 10.1002/jcu.20906. Epub 2011 Nov 22.
3
Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes.
Eur J Clin Invest. 2012 May;42(5):548-56. doi: 10.1111/j.1365-2362.2011.02619.x. Epub 2011 Nov 4.
4
Relationship between serum RANKL and RANKL in bone.
Osteoporos Int. 2011 Oct;22(10):2597-602. doi: 10.1007/s00198-011-1740-9. Epub 2011 Aug 18.
5
Increased intima-media thickness of the carotid artery in childhood: a systematic review of observational studies.
Eur J Pediatr. 2011 Jun;170(6):719-29. doi: 10.1007/s00431-010-1328-y. Epub 2010 Oct 27.
7
Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromsø Study.
J Thromb Haemost. 2010 Oct;8(10):2133-9. doi: 10.1111/j.1538-7836.2010.03990.x.
8
Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?
Wien Med Wochenschr. 2010 Sep;160(17-18):452-7. doi: 10.1007/s10354-010-0818-x. Epub 2010 Aug 16.
9
Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we?
J Am Coll Cardiol. 2010 Jul 6;56(2):98-105. doi: 10.1016/j.jacc.2009.09.081.
10
Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study.
Diabetes Care. 2010 Sep;33(9):2043-8. doi: 10.2337/dc10-0505. Epub 2010 Jun 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验